Last reviewed · How we verify
XL092
XL092 is a small molecule inhibitor of the CDK4/6 pathway.
XL092 is a small molecule inhibitor of the CDK4/6 pathway. Used for Metastatic breast cancer.
At a glance
| Generic name | XL092 |
|---|---|
| Also known as | Zanzalintinib |
| Sponsor | UNC Lineberger Comprehensive Cancer Center |
| Drug class | CDK4/6 inhibitor |
| Target | CDK4/6 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting CDK4/6, XL092 disrupts the cell cycle progression, leading to cell cycle arrest and apoptosis in cancer cells. This mechanism is particularly effective in treating certain types of cancer, such as breast cancer.
Approved indications
- Metastatic breast cancer
Common side effects
- Diarrhea
- Fatigue
- Nausea
Key clinical trials
- A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) (PHASE3)
- A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) (PHASE3)
- Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors (PHASE2, PHASE3)
- H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC) (PHASE2)
- Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03) (PHASE1, PHASE2)
- Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC (PHASE2)
- A Multi-Center Single-Arm Phase 2 Trial Of Zanzalintinib In Combination With Cemiplimab In BRAF Wild-Type Anaplastic Thyroid Cancer: The ZEPHYR Trial (PHASE2)
- Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XL092 CI brief — competitive landscape report
- XL092 updates RSS · CI watch RSS
- UNC Lineberger Comprehensive Cancer Center portfolio CI